Shots:
- The P-III YOSEMITE & RHINE studies assessing faricimab vs aflibercept in 1891 people living with DME. The studies include 3 treatment arms: faricimab (6mg) administered at personalized dosing intervals of ~16wks and at fixed 8wks. intervals & aflibercept (2mg) at fixed 8wks. intervals
- The studies met its 1EPs i.e faricimab in both the doses demonstrated non-inferior visual acuity gains compared to aflibercept and was well tolerated with no new safety signals identified
- Faricimab is the first investigational bispecific Ab targeting 2 distinct pathways i.e., Ang-2 and VEGF-A, currently being evaluated in P-III TENAYA and LUCERNE studies for nAMD
Click here to read full press release/ article | Ref: GlobeNewswire | Image: Forbes
The post Roche Reports Results of Faricimab in Two Global P-III Studies for Diabetic Macular Edema first appeared on PharmaShots.
